Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
Date:3/24/2009

or pixantrone and gain approval in 2009, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, our ability to identify and negotiate product partnerships, our ability to raise additional capital to fund our continued operations, determinations by regulatory, patent and administrative governmental authorities including but not limited to decisions regarding the review and approval of applications submitted to the FDA or the EMEA, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Cell Therapeutics, Inc.
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    Lindsey Jesch
    T : 206.272.4347
    F : 206.272.4434
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Cell Therapeutics, Inc.
    Ed Bell
    T: 206.272.4345
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
2. Oxygen Biotherapeutics, Inc. Expands Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
6. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
7. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
8. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... November 21, 2014 During his lifetime ... the need to surround himself with great people and ... entrepreneur, his friends often marveled at his extraordinarily courageous ... his life and -- even with his death impending—that’s ... Alzheimer’s disease that would ultimately take his life. , ...
(Date:11/22/2014)... Colo. (PRWEB) November 21, 2014 ... proprietary cloud based analytics and scientific testing methodologies relating ... commitment for a $750,000 line of credit from an ... extremely pleased to have secured this commitment from one ... Executive Officer of CannLabs. “This capital will help accelerate ...
(Date:11/22/2014)... 21, 2014 On November 17th Chicago ... 2014 Emerging Medical Technologies Summit in San Francisco to ... Widely regarded among Silicon Valley investors and technology elites ... the win also positions Briteseed to move on ... in 2015 and compete with other elite innovation finalists ...
(Date:11/22/2014)... Respiratory therapy students will soon ... of life-like respiratory ailments using the latest in ... Rapids-based, Michigan Instruments Inc. developers of the world-renowned ... respiratory simulation units to the pro-gram, which cost ... Muskegon Community College are collaborating to offer Muskegon’s ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... , , Introduction , ... , , , Selecting the correct operating parameters for ... Many variables must be considered, , i.e. choosing the appropriate bath ... no surprise to find more , vapors collecting in the lab ...
... , , , , , , , , ... , , 2 , ... 3 , Materials , , , ... , 3.2, Materials required but not supplied , ...
... , , , , PLG can be used in small and ... The basic protocol given here works with E. coli cultures grown for 1214 , ... ml Terrific Broth. , , ... for 5 minutes at room , temperature. , ...
Cached Biology Technology:Optimizing Büchi® Rotary Evaporator Applications 2Optimizing Büchi® Rotary Evaporator Applications 3Optimizing Büchi® Rotary Evaporator Applications 4Optimizing Büchi® Rotary Evaporator Applications 5Optimizing Büchi® Rotary Evaporator Applications 6Optimizing Büchi® Rotary Evaporator Applications 7Optimizing Büchi® Rotary Evaporator Applications 8TripleMaster PCR System 2TripleMaster PCR System 3TripleMaster PCR System 4TripleMaster PCR System 5TripleMaster PCR System 6TripleMaster PCR System 7TripleMaster PCR System 8TripleMaster PCR System 9TripleMaster PCR System 10TripleMaster PCR System 11TripleMaster PCR System 12TripleMaster PCR System 13TripleMaster PCR System 14TripleMaster PCR System 15TripleMaster PCR System 16TripleMaster PCR System 17TripleMaster PCR System 18TripleMaster PCR System 19TripleMaster PCR System 20Basic Plasmid DNA Isolation Protocol 2
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... -Individuals show great diversity in their ability to identify ... greatly differ in their perceptual evaluation of odors, with ... , Sex differences in olfactory detection may ... be connected to one,s perception of smell, which is ... olfactory superiority has been suggested to be cognitive or ...
(Date:11/4/2014)... University School of Medicine announced today that it ... funded by the Bill & Melinda Gates Foundation. ... Gynecology and Reproductive Sciences; and Vice Chair of ... of Medicine will pursue an innovative global health ... to Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... release is also available in Spanish . ... born after preimplantation genetic diagnosis and screening has shown ... growth and risk of congenital malformations. The ... meeting of the European Society of Human Reproduction and ...
... Spanish . , Barcelona, Spain: Children ... the womb have higher birth weight than those born where ... annual conference of the European Society of Human Reproduction and ... and the children did not show an increased risk of ...
... the current drive towards production of alternative fuels from ... into useable compounds are required in industrial quantities and ... from Texas A&M University have come up with a ... Zivko Nikolov, who leads the Bioseparations Lab, will describe ...
Cached Biology News:Embryo biopsy does not affect early growth and risk of congenital malformations in PGD/PGS babies 2Embryo biopsy does not affect early growth and risk of congenital malformations in PGD/PGS babies 3Children born from frozen embryos weigh more and do better than those born after fresh transfer 2A green solution to biofuel production 2
... This modular benchtop fume ... fumes, allowing safe indoor release ... remove most organic contaminants. Configurations ... horizontal flow; options include final ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
...
... These versatile enclosures ... with nitrogen or other ... a low-humidity environment. HEPA ... and ionization modules also ...
Biology Products: